GLP-1 medications could help counteract these effects by: Reducing appetite and food intake
While there is limited evidence that semaglutide specifically reduces laxative effectiveness, patients should be aware that individual responses may vary
Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death
Whats next at Galderma: 2026 launches, GAIN training, and global trends
Table 1 Table 2 Glycemic End Points At 40 weeks, reductions in the mean glycated hemoglobin level with tirzepatide at a dose of 5 mg, 10 mg, and 15 mg were 2.01 percentage points, 2.24 percentage points, and 2.30 percentage points, respectively, as compared with 1.86 percentage points with semaglutide (Figure 1A)